Signaling mechanisms of resistance to EGFR- and Anti-Angiogenic Inhibitors cancer.

摘要: Abstract Colorectal cancer is among four most common malignancies and the second leading cause of death in western world. Epidermal Growth Factor Receptor (EGFR) Vascular Endothelial (VEGF) are often overexpressed colorectal associated with inferior outcomes. More recently, further improvements survival have occurred due to use novel targeted therapies such EGFR Tyrosine Kinase Inibitors (EGFR-TKIs), monoclonal antibodies (EGFR-mAb), VEGF antibodies. Despite initial clinical efficacy these inhibitors cancer, resistance invariably develops, typically within 1 2 years. Over past several years, multiple molecular mechanisms been identified, some themes emerged. One development mutations drug target another it activation alternative signaling key downstream pathways despite sustained inhibition original target. In this mini-review, we summarize concepts underlying EGFR- VEGF-mediated resistance, specific examples known date, challenges applying knowledge develop improved therapeutic strategies prevent or overcome resistance.